Journal of Surgery Concepts & Practice >
Research progress of circulating exosomal miRNA use in diagnosis and treatment of gastric cancer
HUANG Zhiye, LIANG Haibin, CHEN Lei . Research progress of circulating exosomal miRNA use in diagnosis and treatment of gastric cancer[J]. Journal of Surgery Concepts & Practice, 2020 , 25(04) : 354 -358 . DOI: 10.16139/j.1007-9610.2020.04.018
| [1] | Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. |
| [2] | Shen L, Shan YS, Hu HM, et al. Management of gastric cancer in Asia: resource-stratified guidelines[J]. Lancet Oncol, 2013, 14(12):e535-e547. |
| [3] | Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice[J]. Lancet Oncol, 2008, 9(3):279-287. |
| [4] | Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association[J]. Gastric Cancer, 2014, 17(1):26-33. |
| [5] | Mathai RA, Vidya RVS, Reddy BS, et al. Potential utility of liquid biopsy as a diagnostic and prognostic tool for the assessment of solid tumors: implications in the precision oncology[J]. J Clin Med, 2019, 8(3).pii:E373. |
| [6] | Becker A, Thakur BK, Weiss JM, et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis[J]. Cancer Cell, 2016, 30(6):836-848. |
| [7] | Huang T, Song C, Zheng L, et al. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy[J]. Mol Cancer, 2019, 18(1):62. |
| [8] | Ying W, Riopel M, Bandyopadhyay G, et al. Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity[J]. Cell, 2017, 171(2):372-384,e12. |
| [9] | Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105(30):10513-10518. |
| [10] | Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute 2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma[J]. Proc Natl Acad Sci U S A, 2011, 108(12):5003-5008. |
| [11] | Gallo A, Tandon M, Alevizos I, et al. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes[J]. PloS One, 2012, 7(3):e30679. |
| [12] | Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients[J]. Nat Rev Cancer, 2011, 11(6):426-437. |
| [13] | Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends[J]. J Cell Biol, 2013, 200(4):373-383. |
| [14] | Larrea E, Sole C, Manterola L, et al. New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies[J]. Int J Mol Sci, 2016, 17(5).pii:E627. |
| [15] | Liu H, Li PW, Yang WQ, et al. Identification of non-invasive biomarkers for chronic atrophic gastritis from serum exosomal microRNAs[J]. BMC Cancer, 2019, 19(1):129. |
| [16] | Shi Y, Wang Z, Zhu X, et al. Exosomal miR-1246 in serum as a potential biomarker for early diagnosis of gastric cancer[J]. Int J Clin Oncol,2019-09-10. [Epub ahead of print] |
| [17] | Yang H, Fu H, Wang B, et al. Exosomal miR-423-5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer[J]. Mol Carcinog, 2018, 57(9):1223-1236. |
| [18] | Bai M, Li J, Yang H, et al. miR-135b delivered by gastric tumor exosomes inhibits foxo1 expression in endothelial cells and promotes angiogenesis[J]. Mol Ther, 2019, 27(10):1772-1783. |
| [19] | Kumata Y, Iinuma H, Suzuki Y, et al. Exosome-encapsulated microRNA23b as a minimally invasive liquid biomarker for the prediction of recurrence and prognosis of gastric cancer patients in each tumor stage[J]. Oncol Rep, 2018, 40(1):319-330. |
| [20] | Ren W, Zhang X, Li W, et al. Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer[J]. Cancer Manag Res, 2019, 11:4023-4040. |
| [21] | Huang J, Shen M, Yan M, et al. Exosome-mediated transfer of miR-1290 promotes cell proliferation and invasion in gastric cancer via NKD1[J]. Acta Biochim Biophys Sin (Shanghai), 2019, 51(9):900-907. |
| [22] | Liu F, Bu Z, Zhao F, Xiao D. Increased T-helper 17 cell differentiation mediated by exosome-mediated microRNA-451 redistribution in gastric cancer infiltrated T cells[J]. Cancer Science, 2018, 109(1):65-73. |
| [23] | Wang N, Wang L, Yang Y, et al. A serum exosomal microRNA panel as a potential biomarker test for gastric cancer[J]. Biochem Biophys Res Commun, 2017, 493(3):1322-1328. |
| [24] | Huang Z, Zhu D, Wu L, et al. Six serum-based miRNAs as potential diagnostic biomarkers for gastric cancer[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(2):188-196. |
| [25] | Ma M, Chen S, Liu Z, et al. miRNA-221 of exosomes originating from bone marrow mesenchymal stem cells promotes oncogenic activity in gastric cancer[J]. Onco Targets Ther, 2017, 10:4161-4171. |
| [26] | 魏玮, 王艺, 李霖, 等. 5-氟尿嘧啶耐药的晚期胃癌病人血清外泌体miRNA表达谱分析[J]. 肿瘤, 2017, 37(10):1047-1055. |
| [27] | Zheng P, Chen L, Yuan X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells[J]. J Exp Clin Cancer Res, 2017, 36(1):53. |
| [28] | Li BS, Zhao YL, Guo G, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection[J]. PloS One, 2012, 7(7):e41629. |
| [29] | Wang X, Zhang H, Bai M, et al. Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer[J]. Mol Ther, 2018, 26(3):774-783. |
/
| 〈 |
|
〉 |
